|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| C07K 16/18 | (2006.01) |
| (11) | Number of the document | 2990422 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15185749.7 |
| Date of filing the European patent application | 2005-09-02 | |
| (97) | Date of publication of the European application | 2016-03-02 |
| (45) | Date of publication and mention of the grant of the patent | 2018-07-11 |
| (46) | Date of publication of the claims translation | 2018-10-10 |
| (30) | Number | Date | Country code |
| 607377 P | 2004-09-03 | US |
| (72) |
DENNIS, Mark, S., US
FONG, Sherman, US
|
| (73) |
Genentech, Inc.,
1 DNA Way, South San Francisco, CA 94080-4990,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Humanizuoti anti-beta7 antagonistai ir jų panaudojimas |
| HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR |
| Payment date | Validity (years) | Amount | |
| 2022-08-22 | 18 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-09-02 |